Introduction
Over 700,000 Americans have cerebrovascular disease, 13 million have coronary artery disease (CAD), and 12 million have peripheral arterial disease 1 . These conditions often co-exist 2 , resulting in prescription of multiple antithrombotic medications, including anticoagulants (i.e., warfarin) and antiplatelet agents (i.e., ticlopidine, clopidogrel, or aspirin [ASA]). When prescribed in dual or triple combinations, these regimens are considered complex antithrombotic therapies (CAT). Their efficacy in preventing secondary cardiac events must be balanced with their increased risk of gastrointestinal (GI) bleeding (i.e., upper gastrointestinal events [UGIE], including ulcer bleeding and perforation and obstruction; and lower gastrointestinal events [ LGIE], including diverticular bleeding, hemorrhoidal bleeding and bleeding from polyps and other vascular lesions).
The burden of CAT-related GI bleeding remains largely unknown among the elderly, an emerging population of patients systematically excluded from pivotal CAT trials. The best evidence would come from a double-blind, randomized controlled trial with multiple arms that assesses GI bleeding as the outcome of interest. However, this would be unethical, given the known GI bleeding risk factor of advanced age 3 . To quantify the risk of CAT-related GI bleeding , we examined UGIE and LGIE risk and associated transfusions and hospitalizations in a national cohort of elderly patients. Our goal was to quantify the real-life number needed to harm (NNH) associated with CAT-related GI bleeding and measure two patient-centered outcomes (i.e., need for transfusion, and bleeding requiring hospitalization) in a national cohort of elderly patients.
Methods
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[CPT], ICD-9 codes and surgical codes). We also identified patients with evidence of CPT codes for upper or lower endoscopy and/or ICD-9 codes for surgical endoscopy or surgical GI bleeding (diagnostic or hemostatic) procedures.
A test sample was created by matching each potential case by age and gender to 134 potential controls prescribed a CAT regimen during the same period, but without a bleedingrelated diagnostic or procedure code. A full list of administrative codes used in the chartvalidation study is available from the authors. Cases' and controls' charts were abstracted for confirmation of a CAT-related UGIE, LGIE, transfusion or inpatient hospitalization, and a diagnostic algorithm was derived to maximize positive (PPV) and negative predictive value (NPV). These algorithms were then validated in a second independent sample of 100 patients from the last 6 months of 2003.
Outcomes of Interest
Our final diagnostic case-ascertainment algorithm defined CAT-related UGIE as the presence of an ICD-9 code 531, 532, 534 and 569 in any position of the PTF, or code 578 and 533 and a CPT code for upper endoscopy in any position. This algorithm had a PPV of 83% and NPV of 100%.
The CAT-related LGIE algorithm of ICD-9 code 562 or 578 with a CPT or surgical code for bleeding (diagnostic or hemostatic) procedures.
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Assessment of Drug Exposure
Prescription-fill data were assessed on a day-by-day basis; an individual exposure period started at t 0 and ended with final termination of days' supply. Using published methodology 5 exposure was defined to be 1.25 X (number of days supplied) to extend exposure by a conservative grace period during which pharmacologically-induced GI bleeding may occur. An individual would be considered "off the CAT regimen," i.e., time periods with no exposure, when that individual's longitudinal prescription fill data did not demonstrate prescription of the drugs of interest. Each person-day of follow-up within the exposure period was assessed for presence of ACAP, ASAP, ASAC, TRIP (defined by overlapping prescriptions of 5 days or more for each drug of interest) or none. Exposure to CAT strategies and other pharmacological risk factors was considered in a time-varying pattern, assessed for each individual, creating a unique record for each interval for each distinct pattern of prescription-fill data.
Potential Risk Factors and Confounding Variables
Pharmacologic risk factors, including prescription of nonsteroidal anti-inflammatory drugs (NSAIDS), both traditional and COX-2 selective, steroids, selective serotonin reuptake inhibitors (SSRI) and selective norepinephrine reuptake inhibitors, low-molecular-weight heparin, and at t 0 and ended with final termination of days' supply. Using published methodo olo lo ogy gy gy f 5 heparin overlapping with CAT prescription, were identified (Supplemental Table 2 ). We also assessed exposure to proton pump inhibitors (PPIs), statins and selective serotonin reuptake inhibitors; shown to modify GI bleeding risk 6, 7 . Models were also adjusted for demographics (age, gender, race), Helicobacter pylori (H. pylori) infection (using our previously validated algorithm) 8 and a time-dependent Elixhauser comorbidity Index score 9 ( Table 1) . Unadjusted analyses were used to assess patient characteristics that might be associated with a greater likelihood of being prescribed a particular prescription strategy (i.e., confounding by indication); prescription of a PPI or triple therapy were associated with unique patient characteristics that influenced outcomes in unadjusted analyses. Thus, a propensity score 10 was calculated to estimate the conditional probability of a patient being prescribed a PPI or triple therapy.
Survival analyses were then stratified by propensity score quintiles to adjust for bias when estimating treatment effects 11 and treatment effect was assessed within each stratum.
Analytic Methods
The chi-square test and ANOVA were used to test for differences in demographic and clinical PHREG procedure was used to analyze data at each UGIE, LGIE hospitalization and transfusion comparing individuals with the event to those still uncensored without the event. The Wald's Chi-Square test was used to test for significance of the influence of each independent variable. estimate the conditional probability of a patient being prescribed a PPI or triple t th he h ra r r py py py. .
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Results
The study population included 78,133 veterans (98.6% white; mean age, 72.3 [SD 7.7]) prescribed dual or triple CAT ( Table 1) ; 64% had been prescribed an antiplatelet-based strategy (ASAP and ACAP), and 6% had been prescribed TRIP. Baseline characteristics are described in Table 1 . There were no significant differences among CAT strategies with regard to history of UGIE or gastroesophageal reflux disease, and concomitant NSAID prescription overall ranged from 7 to 34%. The prevalence of H. pylori infection was also similar among subgroups (p=0.103).
The mean duration of follow-up time for cohort members was 838 days (SD: 548 days) or 2.3 years. The mean duration of time on ACAP was 548 days (SD: 488), on ASAP was 632 days (SD: 495), on ASAC was 493 days (SD: 475) and TRIP was 355 days (SD: 398). The time during which cohort members were on no drugs of interest (i.e., no exposure/none) was 317 days (SD: 335). Unadjusted incidence density and IDR for each outcome of interest, during the 2.3 years of total observation, is shown in Table 2 and are presented with the reference category of none (i.e., no CAT exposure). The overall incidence of UGIE with antithrombotic use was 20.1/1000 PY of follow-up. The greatest risk was observed with triple CAT. The overall risk of prescribed dual or triple CAT ( Table 1) ; 64% had been prescribed an antiplatele et-t t-ba ba ase se ed d d st st stra ra rat te tegy gy g ASAP and ACAP), and 6% had been prescribed TRIP. Baseline characteristics are described in lower GI bleeding was 70.1/1000 PY, with greatest risk seen with ACAP and TRIP. Patients prescribed ASAC and TRIP had the greatest incidence of transfusion and hospitalization. The IDR compared each incidence density to no CAT exposure and was stable in most cases. It did increase with each CAT strategy except when the incidence density of the "none category" for that outcome (i.e., transfusion, hospitalization) exceeded that of a specific CAT prescription strata. In these CAT strata, the IDR appeared falsely protective; however, the 95% CI overlap suggested no significant difference. The NNH was calculated in the first 365 days following index prescription to report the number of patients needed to be treated with a particular drug strategy to incur one additional outcome of interest ( Table 3) T Th T e es ese models re ev ve e eale led d a a a 40 40% % % to to 6 6 60% 0% 0% i in nc crea a ase e ed ri i isk k k of f f UG UG UGIE IE E wi ith h h all l CA CA CAT T T st st tra rate teg gi g e es es. A A Amo mong g g pa pati ti ien en ents ts ts p p pre re res sc scri ribe be bed d d AC AC ACAP AP AP the he ere re re w w wa as as a a 3 3 30% 0% 0% i inc nc ncr r rea ea ease se se i in n n LG LG LGIE IE IE. . Th Th The e e ri ri risk sk k o o of f f tr tran an nsf sf sfus us usio io ion n wa wa was s s ncreased 6--fo fo fold ld ld w w wit it ith h h AS AS A AC AC AC p pre esc sc cri ri ip ptio io on n n (H (H (HR R R 6 6. 6 1; 1; 1 9 9 95% 5% 5% C C CI: I: I 5 5 5.2 2 2-7 -7 7.1 1 1) ) ) an an and d d 5-5-5 fo fo f ld ld ld h h hig ig ighe he her r with TRIP P P
LGIE. The NNH for ASAC, ASAP and ACAP ranged from 15-19, respectively. The LGIE NNH for TRIP was slightly greater at 23. As few as 16 patients prescribed ASAC resulted in an additional transfusion risk; risk of transfusion was least among patients prescribed ASAP. Table   3 demonstrates the frequency of expected hospitalizations associated with the prescriptions of interest. The NNH to incur 1 additional GI bleeding-related hospitalization was 39, 34, 67 and 45 patients for ACAP, ASAC, ASAP and TRIP, respectively ( Table 3) .
Sensitivity Analyses
A 1-way threshold sensitivity analysis using Monte Carlo methodology 13 generated replicates of the original dataset assuming random and nonrandom misclassification of over-the-counter (OTC) ASA, NSAIDs or PPI. We set the drug-use indicator for each subject at 10%, 25% and 50% misclassification for each drug and examined the impact of variation on CAT-related bleeding risk. The results for our outcomes of interest did not meaningfully change in magnitude or direction of effect (data not shown), confirming the robustness of our initial models.
Discussion
Secondary cardioprotection trials [14] [15] [16] [17] [18] [19] reveal an absolute benefit of CAT ranging from ~0.6% to 16 .5%. However, this benefit must be balanced against the risk of GI bleeding. An 
randomized controlled CAT trials. To our knowledge, this is the largest study investigating the GI bleeding risk associated with both the upper and lower GI tract, which also quantifies that risk as patient-centered outcomes: need for blood transfusion and bleed-related hospitalization.
This real-world sample of elderly, comorbid patients demonstrated the substantial risk for lower as well as upper GI bleeding following complex antithrombotic therapy and the high rate of hospitalization and need for transfusions associated with these GI bleeding events.
The average age of our population (72.5 years) reflects the rapidly growing cohort of elderly cardiovascular patients and mirrors increased use of interventional cardiology and modern surgical management of atherosclerotic disease among elderly Americans ( 70 years).
Frequently, more complex pharmacological regimens are recommended to treat a postintervention population, reflected (in our study) in a much higher proportion of TRIP therapy in those 70 years than anticipated. These individuals were also more likely to be co-prescribed
NSAIDs, SSRI and steroids, further increasing their risk of GI bleeding events. The incidence- Similar to our study, Grove et al. 21 highlighted GI adverse events associated with Our studies also differ by methodology. Rather than perform a case-control study, we chose a rigorous pharmacoepidemiologic method of capturing each cohort member's exposure time to prescriptions of interest on a day-by-day basis and compared the associated risk of individual exposure time to that in gap periods (i.e., no exposure). Thus, patients were not artificially matched to controls; their periods of CAT exposure were compared to periods off CAT within the same high-risk cohort. This more realistically reflects the real-life experience and natural history of CAT exposure risk in a highly vulnerable, comorbid, elderly cardiovascular population 24, 25 .
NSAIDs such as low-dose ASA increase the risk of major bleeding ~2-fold over placebo (RR= 1.71; 95% CI: 1.41-2.08) 26 and cause both UGIE and LGIE bleeding by direct injury to GI mucosa, causing ulceration and erosions, and via platelet thromboxane A2 production, which can exacerbate luminal bleeding from GI abnormalities, including vascular lesions, diverticulosis and hemorrhoids [27] [28] [29] . ASA injury as the likely "inciting factor" is supported by our data, which demonstrate a 40-60% increased risk of UGIE and 10-20% increased risk of LGIE with ASAP, riple combinations, including ASA and anticoagulants.
Our studies also differ by methodology. Rather than perform a case-cont ntro ro rol l l st st stud ud udy, y, y, w w we e e chose a rigorous pharmacoepidemiologic method of capturing each cohort member's exposure Limitations of our data must be acknowledged. Members of our cohort were still at risk of GI bleeding-related outcomes during gap periods of nonexposure to CAT therapy, likely explained by the significant overall comorbidity of these patients and residual confounding insufficiently addressed by propensity scores and consideration of prescription channeling. In observational studies selection bias and residual confounding cannot be entirely excluded.
Furthermore, the observational nature of the study can support only associations of risk and cannot speak to causality. We anticipated our inability to capture OTC ASA, PPI and NSAIDs and addressed this by examining random and nonrandom misclassification of exposure to these, using a 1-way threshold sensitivity analysis of "worse-case scenarios," assuming 10%, 25% and 50% misclassification among patients of higher socioeconomic status (priority group 8 or top quintile income-level zip code). Our data demonstrate robust outcome estimates, even assuming 50% underreporting of OTC ASA, NSAID, or PPI exposure.
Our study is limited by the accuracy of exposure and outcome ascertainment using administrative data. We have minimized this by validating both the pharmacy-fill data and Limitations of our data must be acknowledged. Members of our cohort w we were re re s s sti ti ill ll ll a a at t t r ri risk sk r of GI bleeding-related outcomes during gap periods of nonexposure to CAT therapy, likely are assigned a priority group, based on service-connected and other disability, income and special considerations 31 . High-priority" veterans have a service-connected condition and an income less than an annual threshold established by the VA and tend to obtain all their care at VA facilities 32 . "Low-priority" veterans have higher socioeconomic status and may be more likely to be treated at non-VA facilities. Thus, the Cox-Proportional Models were stratified by priority-group level (low priority vs. other). To further minimize the impact of underascertainment, we restricted our cohort to regular VA users; who are more likely to be treated at a VA facility. As with any study that uses prescription-fill data as the source of exposure, we can only assess prescription-fill, not actual use of the drug-but this again, is a limitation of any observational study that uses pharmacy fill data and not unique to our study. Lastly, our sample was predominantly male veterans, which may limit generalizability to nonveterans. We do not believe this is significant, as male gender is a known risk factor for atherosclerosis; and GI bleeding-risk is not gender specific. Thus, our cohort is likely an ideal high-risk cohort for examination of CAT-related GI bleeding epidemiology.
Our data should serve as a caution to prescribing physicians and encourage vigilance in prescribing CAT beyond the necessary therapeutic window. Current ACC/AHA guidelines do not recommend dual antiplatelet therapy in patients with stable chronic CAD and no recent acute coronary syndrome (<12 months) but do recommend it in post-PCI patients with a drug-eluting stent. Even among the latter, recommendations for chronic CAT (ASAP, TRIP) beyond 12 months are unjustified in most 33 . These recommendations may change, as the EXCELLENT and PRODIGY trials have both recently shown that 6-month dual antiplatelet therapy is sufficient in most patients at low risk of restenosis following implantation of drug-eluting stents can only assess prescription-fill, not actual use of the drug-but this again, is a li limi mi mit ta tat ti tion on on o o of f f an any y observational study that uses pharmacy fill data and not unique to our study. Lastly, our sample wa wa as s s p pr pre edom om min in nan ntl tl tly y m male veterans, which may lim im mit t generalizabilit it ity y to o n non onveterans. We do not be b li i iev e e this is si sign gn gnif fic ican an nt, a as s m ma male le g g gen ende de er is a know ow wn n ri ri isk sk sk f f fa a acto tor fo or r ath h her ro osc sc cle e ero rosi sis s; s a an nd d G G GI bl blee ee edi di ding ng ng-r -r -ris is isk k k is is s n n not ot ot g g gen en ende de der r sp p pec ec ecif if fic ic ic. T Thu hu hus, s, s, o o our ur ur c c coh oh ohor or ort t is is is l l lik ik ikel el ely y y an an n i i ide de dea a a r r r l l l hi hi high gh g -r -r -ris is isk k k co co coho ho ort rt rt f f for or or examination n of of of C C CAT AT AT-r -r rel el lat a ed ed ed G G GI I I bl bl blee ee edi ding ng ng e e epi pi pide de d mi mi miol ol olog og ogy. y 34, 35 . Future work is required to quantify the GI risk-cardioprotective benefit ratios among the elderly for both short-and long-term secondary cardioprevention medication management strategies. Furthermore, the use of patient-oriented outcomes such as bleeding-related hospitalization and need for transfusion is important for quantifying risk-benefit ratios in a manner that is salient to older, morbid patients.
Our study demonstrates CAT prescription is associated with a clinically significant risk of UGIE, LGIE and bleed-related transfusion and hospitalization. These data are important to consider when counseling elderly patients regarding the potential risk-benefit of CAT prescription strategies and further highlight the importance of risk-stratification and riskmodification of vulnerable elders by minimizing time on CAT and ensuring that prescription occurs within the context of safer prescribing habits, as outlined by concerned GI and cardiology societies 20 .
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